Extrait

Prospective, double-blind, randomized, placebo-controlled First-In-Human study with three sub-parts: Part A, a single ascending dose study (SAD) in normal human volunteers (NHVs), Part B, a multiple ascending dose study (MAD) in NHVs, Part C, a multiple dose (MD) study in patients with a complement-mediated disorder.

Critère d'inclusion

• Bullous Pemphigoid (BP),Cold agglutinin disease,Warm Autoimmune Hemolytic Anemia,End-Stage Renal Disease (ESRD)

Liens

• ictrp
• nct